secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001723128-23-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q4 revenue $610M (+14% YoY), adj. EBITDA $154M; FY23 guidance $2.25-2.35B
--------------------------------------------------------------------------------

- Q4 2022 net revenue $610M (+14% YoY); GAAP net loss $4M ($0.03 loss per share).
- Q4 adjusted net income $71M, adjusted EBITDA $154M (+26% YoY), adjusted diluted EPS $0.23.
- Full year 2022 net revenue $2.21B (+6% YoY); GAAP net loss $130M ($0.86 loss per share) including $263M Opana litigation charge.
- Full year adjusted EBITDA $514M (+$2M YoY), adjusted diluted EPS $0.68.
- 2023 guidance: net revenue $2.25-2.35B, adjusted EBITDA $500-530M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/amrx-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001723128-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer